BNGO(4h) Technical ChartBionano Genomics, Inc.
Formation: Falling Wedge Pattern
SL-6.56$
TP1-9.63$
TP2-11.65$
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.5668EUR
−210.64 MEUR
32.72 MEUR
68.45 M
About Bionano Genomics, Inc.
Sector
Industry
CEO
Robert Erik Holmlin
Website
Headquarters
San Diego
Employees (FY)
344
Founded
2003
FIGI
BBG00LKZSBJ8
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Bionano Genomics Inc. stocks are traded under the ticker 2Y30.
We've gathered analysts' opinions on Bionano Genomics Inc. future price: according to them, 2Y30 price has a max estimate of 6.25 EUR and a min estimate of 1.84 EUR. Watch 2Y30 chart and read a more detailed Bionano Genomics Inc. stock forecast: see what analysts think of Bionano Genomics Inc. and suggest that you do with its stocks.
Yes, you can track Bionano Genomics Inc. financials in yearly and quarterly reports right on TradingView.
Bionano Genomics Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
2Y30 earnings for the last quarter are −0.56 EUR per share, whereas the estimation was −0.60 EUR resulting in a 6.85% surprise. The estimated earnings for the next quarter are −0.39 EUR per share. See more details about Bionano Genomics Inc. earnings.
Bionano Genomics Inc. revenue for the last quarter amounts to 8.13 M EUR, despite the estimated figure of 7.86 M EUR. In the next quarter, revenue is expected to reach 7.49 M EUR.
2Y30 net income for the last quarter is −29.12 M EUR, while the quarter before that showed −39.77 M EUR of net income which accounts for 26.77% change. Track more Bionano Genomics Inc. financial stats to get the full picture.
No, 2Y30 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 29, 2024, the company has 344.00 employees. See our rating of the largest employees — is Bionano Genomics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bionano Genomics Inc. EBITDA is −99.27 M EUR, and current EBITDA margin is −348.10%. See more stats in Bionano Genomics Inc. financial statements.
Like other stocks, 2Y30 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bionano Genomics Inc. stock right from TradingView charts — choose your broker and connect to your account.